These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12187203)

  • 1. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder.
    Herr HW; Donat SM; Dalbagni G
    J Urol; 2002 Sep; 168(3):978-80. PubMed ID: 12187203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder?
    Herr HW
    BJU Int; 2001 Nov; 88(7):683-5. PubMed ID: 11890237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of low grade papillary bladder tumors.
    Herr HW; Donat SM; Reuter VE
    J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expectant management of small, recurrent, noninvasive papillary bladder tumors.
    Soloway MS; Bruck DS; Kim SS
    J Urol; 2003 Aug; 170(2 Pt 1):438-41. PubMed ID: 12853794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer.
    Dalbagni G; Han W; Zhang ZF; Cordon-Cardo C; Saigo P; Fair WR; Herr H; Kim N; Moore MA
    Clin Cancer Res; 1997 Sep; 3(9):1593-8. PubMed ID: 9815848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Watchful waiting policy in recurrent Ta G1 bladder tumors.
    Gofrit ON; Pode D; Lazar A; Katz R; Shapiro A
    Eur Urol; 2006 Feb; 49(2):303-6; discussion 306-7. PubMed ID: 16413659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression.
    Holmang S; Johansson SL
    J Urol; 2002 Apr; 167(4):1634-7. PubMed ID: 11912378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm.
    Donat SM; North A; Dalbagni G; Herr HW
    J Urol; 2004 Feb; 171(2 Pt 1):636-9. PubMed ID: 14713776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can urologists accurately stage and grade urothelial bladder cancer by assessing endoscopic photographs?
    Dekalo S; Matzkin H; Mabjeesh NJ
    J Telemed Telecare; 2018 Oct; 24(9):603-607. PubMed ID: 28920525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urothelial carcinoma of the bladder: evaluation by combined endoscopy and urine cytology: is incontrovertible assessment possible?].
    Hess J; Tschirdewahn S; Szarvas T; Rossi R; Rübben H; Vom Dorp F
    Urologe A; 2011 Jun; 50(6):702-5. PubMed ID: 21465088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cystoscopic impression versus histologic diagnosis in bladder tumors. Do they coincide?].
    de León Morales E; Arango Toro O; Lorente Garín JA; Cortadellas Angel R; Bielsa Gali O; Gelabert Mas A
    Actas Urol Esp; 2003 Jan; 27(1):18-21. PubMed ID: 12701493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence and progression in low grade papillary urothelial tumors.
    Holmäng S; Hedelin H; Anderström C; Holmberg E; Busch C; Johansson SL
    J Urol; 1999 Sep; 162(3 Pt 1):702-7. PubMed ID: 10458347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome.
    Herr HW
    J Urol; 2000 Jan; 163(1):60-1; discussion 61-2. PubMed ID: 10604314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of Multisequence Magnetic Resonance Imaging for Detection of Recurrent Tumor After Transurethral Resection for Bladder Cancer.
    Rosenkrantz AB; Ego-Osuala IO; Khalef V; Deng FM; Taneja SS; Huang WC
    J Comput Assist Tomogr; 2016; 40(2):201-5. PubMed ID: 26760195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?
    Hentschel AE; van Rhijn BWG; Bründl J; Compérat EM; Plass K; Rodríguez O; Henríquez JDS; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Scavarda-Lamberti A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Cohen D; Lunelli L; Cussenot O; Sheikh SE; Volanis D; Coté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Babjuk M; van der Kwast TH; Sylvester RJ
    Urol Oncol; 2020 May; 38(5):440-448. PubMed ID: 31704141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
    Guney S; Guney N; Canogullari Z; Ergenekon E
    Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.